RxDoctor Payments Data

Christina Carbone

Acute Care · Cherry Hill, NJNPI 1033811468

Payments from drug & device makers

$1,192in general payments, 2019–2025

Across 19 payments — averaging $62.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$206
  • E.r. Squibb & Sons, L.L.C.$195
  • Pharmacosmos Therapeutics Inc.$146
  • Jazz Pharmaceuticals Inc.$139
  • Novocure Inc.$134
  • Amgen$125
  • plus $247 from 5 others

What the payments were for

  • Food & beverage$1,192100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,192 in reported general payments places this provider in the 75th percentile of 656 acute care providers in New Jersey.

See all acute care providers in New Jersey

Medicare billing

Part B allowed, 2024
$102,277
Medicare patients
244
Services billed
1,224

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib28$443,048
LenvimaLenvatinib Mesylate13$296,144
XtandiEnzalutamide21$278,295
RevlimidLenalidomide15$251,513
ImbruvicaIbrutinib17$239,699
InlytaAxitinib11$212,051
CalquenceAcalabrutinib Maleate16$177,076
EliquisApixaban101$69,878
Imatinib Mesylate34$45,224
OrgovyxRelugolix15$39,432
XareltoRivaroxaban17$19,981
CreonLipase/Protease/Amylase12$14,790
ValacyclovirValacyclovir Hcl17$2,205
Hydroxyurea48$1,675
Prochlorperazine Maleate56$803

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$16$251,51315 claims
AstraZenecaCalquence$206$177,07616 claims
Johnson & JohnsonXarelto$19$19,98117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 656 acute care providers in New Jersey.

Other acute care in Cherry Hill

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →